The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are
Achieving and maintaining a high-quality response is the treatment goal for patients with newly diagnosed multiple myeloma (NDMM)
In this video: Pau G
Multiple myeloma (MM) is an incurable plasma cell disorder that usually produces monoclonal immunoglobulins (M-protein or monoclonal component)
49 Recently, a
Thalidomide works in different ways
Panobinostat and bortezomib are types of targeted cancer drugs called cancer growth blockers
Compared with Vd, XVd was associated with sig
The survival ranges from few months to more than 10 years with the availability of novel agents such as thalidomide, lenalidomide, and bortezomib over recent years
Background: Bortezomib, lenalidomide, and dexamethasone (VRd) is a standard therapy for newly diagnosed multiple myeloma
This publication is part of our Treatment Guide series, a collection of publications covering different drugs used in the treatment of myeloma
This drug is used with dexamethasone: For people whose myeloma has been treated with and no longer responds to at least several other myeloma drugs, OR; Along with bortezomib for adults whose myeloma has grown on at least one other drug therapy
Micro abstractDaratumumab, lenalidomide, dexamethasone (DRd) and bortezomib, lenalidomide, dexamethasone (VRd) are the preferred first-line regimens for transplant-ineligible newly diagnosed multiple myeloma, but there is no head-to-head study comparing these regimens
Patients and methods: Eligible patients had received ≥ 1 line of treatment and were
Lenalidomide and dexamethasone with bortezomib (VRd) or carfilzomib (KRd) are commonly used induction regimens in the U
Responses were rapid with a mean 80% decline in the sentinel Daratumumab, a CD38 human monoclonal antibody, demonstrated significant clinical activity in combination with bortezomib and dexamethasone versus bortezomib and dexamethasone alone in the primary analysis of CASTOR, a phase 3 study in relapsed and/or refractory multiple myeloma